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10, D-13125 Berlin, Germany.Voltage-dependent human ether à go-go (hEAG1) potassium channels are implicated in neuronal
signaling as well as in cancer cell proliferation. Unique sensitivity of the channel to intracellular
Ca2+ is mediated by calmodulin (CaM) binding to the intracellular N- and C-termini of the channel.
Here we show that application of the acidic calcium-binding protein S100B to inside-out patches of
Xenopus oocytes causes Ca2+-dependent inhibition of expressed hEAG1 channels. Protein pull-down
assays and ﬂuorescence correlation spectroscopy (FCS) revealed that S100B binds to hEAG1 and
shares the same binding sites with CaM. Thus, S100B is a potential alternative calcium sensor for
hEAG1 potassium channels.
Structured summary:
MINT-7988123:CaM (uniprotkb:P62158) andEAG1alpha (uniprotkb:O95259) physically interact (MI:0915)
by competition binding (MI:0405)
MINT-7988019, MINT-7988052:EAG1 alpha (uniprotkb:O95259) binds (MI:0407) to s100B (uni-
protkb:P02638) by pull down (MI:0096)
MINT-7988074: EAG1 alpha (uniprotkb:O95259) and s100B (uniprotkb:P02638) physically interact
(MI:0915) by competition binding (MI:0405)
MINT-7988100: CaM (uniprotkb:P62158) and EAG1 alpha (uniprotkb:O95259) bind (MI:0407) by ﬂuores-
cence correlation spectroscopy (MI:0052).
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction C-termini of the channel proteins [8–10]. Thus, ether à go-goHuman ether à go-go (hEAG1, KCNH1) potassium channels are
voltage-gated potassium channels, ubiquitously expressed in neu-
ronal tissues and presumably functioning in neuronal signaling [1].
Interest in hEAG1 channel research has been fueled by studies on
cancers such as neuroblastoma [2], melanoma [3], and soft tissue
sarcoma [4] showing that these channels play an essential role in
tumor proliferation and progression [5,6]. One of the hallmark fea-
tures of hEAG1 channels is their sensitivity to intracellular Ca2+ [7]
with a half-maximal inhibition concentration of 100 nM. Our
previous studies showed that the Ca2+ sensitivity is mediated by
calmodulin (CaM), which binds to motifs in cytosolic N- andchemical Societies. Published by E
go; FCS, ﬂuorescence correla-
hoo), troeger@fmp-berlin.de
emann), roland.schoenherr@
rlin-Buch, Robert-Roessle-Str.(EAG) channels are under strong negative control by the intracellu-
lar Ca2+ concentration ([Ca2+]i). This feature may be a critical link to
the putative role of hEAG1 channels in cell proliferation and tumor
progression because changes in [Ca2+]i have a regulatory function
in the cell cycle [11]. We thus asked if there are alternative Ca2+-
binding proteins that regulate hEAG channels and that might be
important in neuronal or tumor cells.
Potential candidates are S100 proteins, which often share
molecular interaction sites with CaM [12]. S100 proteins belong
to the S100/CaM/parvalbumin/troponin C super family of Ca2+-
binding proteins [12–14]. S100B is the best-characterized member
of this family; it has a molecular mass of 10.6 kDa and harbors two
Ca2+-binding sites of the EF-hand type [15]. S100B is active as a
homodimer and therefore has some similarity to CaM, which har-
bors 4 EF-hand sites as a monomer [16]. Intracellular S100B is
known to interact with more than 25 different proteins in a Ca2+-
dependent manner, including membrane proteins such as dopa-
mine D2 receptors [17–19]. S100B is also secreted by astrocytes
and other cell types and exerts effects on neurons, astrocytes and
various other cell types [18]. In neurons, extracellular S100Blsevier B.V. All rights reserved.
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concentration, whereas at micromolar concentration it induces
apoptosis [20]. Elevated intratumoral levels of S100B have been
detected in malignant melanoma and to a lesser extent in thyroid
carcinoma and renal cell carcinoma [21]. These observations
prompted us to investigate whether S100B has a functional impact
on hEAG1 channels.2. Materials and methods
2.1. Construction of expression vectors
Cloning of full-length cDNA encoding human EAG1 (hEAG1,
KCNH1) and hCaM, generation of hEAG1 point mutations in C1
(R675N-R677N-R681N-K682N) and C2 (F714S-F717S) (Fig. 2A),
insertion into pGEX-5X (Amersham Biosciences) and pQE30 (Qia-
gen) for expression of GST-tagged hEAG1 fusions and His6-tagged
hCaM, respectively, were previously described by Schönherr et al.
[8]. The N-terminal deletion mutant of hEAG1 (DN, hEAG1D2-
190) was described by Ziechner et al. [9].
2.2. Protein puriﬁcation and pull-down assay
His6-tagged hCaM was expressed in Escherichia coli M15 cells
and puriﬁed using Ni-NTA agarose. GST-fusion proteins were ex-
pressed in E. coli BL21 cells and puriﬁed using GSH-sepharose.
For the pull-down assay, GSH-sepharose beads with immobilized
GST fusions were ﬁrst washed with Ca2+-free (10 mM ethylenedi-
aminetetraacetic acid (EDTA), in PBS pH 7.4) or Ca2+-containing
(10 mM EDTA, 35.6 mM CaCl2 in PBS pH 7.4) buffer and incubated
with Ca2+-free or Ca2+-containing buffer supplemented with bovine
S100B (Calbiochem, Cat. No. 559290, Germany) for 1 h on a rocking
platform at 4 C. The purity of S100B and absence of CaM from the
sample was veriﬁed by MALDI-MS analysis. The ﬁnal concentration
of S100B was 90 lM. After S100B incubation, sepharose beads
were washed twice with 500 ll of Ca2+-free or Ca2+-containing buf-
fer supplemented with 0.1% NP-40, followed by two washing steps
with NP-40 free buffers. GST fusions and bound proteins were
eluted by boiling samples in 30 ll SDS–PAGE loading buffer. Sam-
ples were analyzed by separation on a denaturing SDS–polyacryl-
amide gel and proteins were visualized by Coomassie staining.
S100B was detected by a polyclonal rabbit antibody (DakoCytoma-
tion, Denmark) after blotting onto a polyvinylidene ﬂuoride mem-
brane as previously described [8].
2.3. Electrophysiological measurements
Capped mRNA was synthesized in vitro using the mMessage
mMachine kit (Ambion, Austin, TX, USA). Stage-V oocytes from
Xenopus laevis were surgically obtained under ice water/tricaine
anesthesia according to the local animal care program. Currents
were measured 2–4 days after mRNA microinjection (<50 nl per
cell) in the inside-out patch-clamp conﬁguration using aluminum
silicate glass pipettes with resistances of 1–2 MX and an EPC-9
ampliﬁer operated with PatchMaster software (both HEKA Elektro-
nik, Lambrecht, Germany). The bath solutions contained (in mM):
‘1-lM Ca2+’: 115 K-aspartate, 10 glycol-bis(2-aminoethylether)-
N,N,N0,N0-tetraacetic acid (EGTA), 8.73 CaCl2, 10 HEPES (pH 7.2 with
KOH) or ‘Ca2+-free’: 100 K-aspartate, 10 EGTA, 15 KCl, 10 HEPES
(pH 7.2 with KOH). The pipette solution contained (in mM):
103.6 Na-aspartate, 11.4 KCl, 1.8 CaCl2, 10 HEPES (pH 7.2 with
NaOH). For solutions with varying Ca2+ concentration, we used
10 mM HEDTA (pH 8.0) and varied concentrations of CaCl2, as cal-
culated using Max Chelator software (http://www.stanford.edu/
~cpatton/webmaxc/webmaxcE.htm; [22]). Human EAG1 (KCNH1)in the mammalian cell expression vector pcDNA3 (Invitrogen)
was transiently expressed in HEK293 cells using Superfect trans-
fection kit (Qiagen). Dynabeads (Deutsche Dynal GmbH, Hamburg,
Germany) were used for visual identiﬁcation of individual cells,
cotransfected with CD8. Whole-cell voltage-clamp experiments
were carried out 2–3 days after transfection. Patch pipettes with
resistance 0.9–2 MOwere used. The series resistance was compen-
sated for by more than 70% in order to minimize the voltage error.
The solutions used for extracellular application of S100B were (in
mM): bath, 135 NaCl, 5 KCl, 2 CaCl2, 10 HEPES (pH 7.4 with NaOH)
and pipette, 130 KCl, 2.56 MgCl2, 10 EGTA, 10 HEPES (pH 7.4 with
KOH). The solutions used for intracellular application of S100B
were (in mM): bath, 125 K-aspartate, 5 CaCl2, 10 HEDTA, 10 HEPES
(pH 8.0 with KOH) and pipette, 119 K-aspartate, 6 KCl, 2 MgCl2, 10
HEPES (pH 8.0 with KOH). For application of His6-tagged hCaM and
S100B, the puriﬁed protein was transferred to HEPES buffer (in
mM: 100 K-aspartate, 15 KCl, 10 HEPES pH 7.2) via PD10 columns
(Amersham-Pharmacia). Change of solutions was performed using
a multi-channel perfusion system and the patch was placed di-
rectly in the center of the streaming solution.
Data were analyzed with FitMaster (HEKA Elektronik) and Igor-
Pro (WaveMetrics, Lake Oswego, OR, USA). Data are presented as
mean ± S.E.M. (n = number of independent measurements).
2.4. Confocal ﬂuorescence correlation spectroscopy (FCS)
Labeling of hCaM and FCS measurements was performed as pre-
viously described by Ziechner et al. [9]. The amount of Cy5-labeled
MCGS-His6-hCaM in complex with a GST fusion of the hEAG1 C-ter-
minus (GST-C2B34) was measured and the ratio of complex-bound
to free labeled hCaM after addition of unlabeled hCaM or His6-
S100B was determined using the ConfoCor-2 software (Carl Zeiss
AG, Germany). Binding of GST-C2B34 increased the diffusion coefﬁ-
cient of MCGS-His6-hCaM and competition with unlabeled hCaM or
His6-S100B subsequently decreased the diffusion coefﬁcient.3. Results
3.1. S100B inhibits hEAG1 channels in a Ca2+-dependent manner
Potassium current of hEAG1 channels was measured from
membrane patches in the inside-out conﬁguration. While exposure
of the cytosolic membrane face to solutions containing 1 lM S100B
in the absence of Ca2+ did not affect the current magnitude, 1 lM
S100B in the presence of 1 lM Ca2+ strongly reduced the mean cur-
rent within 30 s (Fig. 1A and B) yielding a block of 78 ± 4.6% (n = 5).
Current kinetics was not altered indicating that the channels are
blocked with no noticeable inﬂuence on channel gating. Washout
of S100B in the presence of 1 lMCa2+ resulted in full recovery from
channel inhibition with a time constant of about 100 s (Fig. 1B).
Current block by S100Bwas assayed for various voltages (60 to
+60 mV) indicating that the action of S100B does not depend on the
membrane potential and that there is no obvious use-dependence.
The steady-state voltage dependence of hEAG1 was unaffected by
the presence of S100B (Fig. 1C). The concentration dependence of
S100B-inducedhEAG1channel block is shown in Fig. 1D. Fits to aHill
equationyieldedan IC50 valueof 282 ± 36 nMS100B, assumingaHill
coefﬁcient of unity. Current inhibition by CaM with an IC50 of
6.1 ± 0.9 nM is shown for comparison.
It is not uncommon that mammalian channels exhibit altered
functional properties upon expression in Xenopus oocytes. To rule
out such effects we expressed hEAG1 in HEK293 cells and applied
S100B in the inside-out patch-clamp conﬁguration. Patch perfusion
with 5 lM S100B in the presence of 1 lM free Ca2+ resulted in
95.3 ± 0.9% current block (n = 4; data not shown). Since S100B is also
Fig. 1. Block of hEAG1 channels by S100B. (A) Pulse protocol (top) and superposition of current responses in inside-out patches from Xenopus oocytes expressing hEAG1
channels under control conditions, after application of 1 lM S100B in Ca2+-free solutions or in solutions containing 1 lM free Ca2+. (B) Mean current at the end of the test
depolarizations to +40 mV as a function of time. Starting in Ca2+-free solutions the inside-out patch was exposed to 1 lM S100B and then to 1 lM S100B plus 1 lM Ca2+. Filled
symbols denote data points from traces shown in (A). (C) Current–voltage relationships before (open) and after application (ﬁlled circles) of 1 lM S100B in 1 lM Ca2+ (n = 5).
Filled squares are the relative block, i.e., I(S100B)/I(control), indicating voltage-independence of block. Data points are connected by straight lines. (D) Concentration–
response curves for the block of hEAG1 current in 1 lM Ca2+ by S100B (circles) and CaM (squares). Continuous curves are Hill ﬁts with a Hill coefﬁcient of one and apparent
IC50 values of 6.1 ± 0.9 nM for CaM and 282 ± 36 nM for S100B. (E) The calcium dependence of hEAG1 current inhibition by Ca2+/S100B was measured at +40 mV with a
constant concentration of S100B (500 nM). The concentration dependence was described with a Hill equation yielding an apparent IC50 value of 0.48 ± 0.36 lM, a Hill
coefﬁcient of 1.3 ± 0.3, and a remaining current fraction of 0.20 ± 0.20 (n = 3–9).
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applied fromtheextracellular side. Assayed in thewhole-cell conﬁg-
uration upon channel expression in HEK293 cells, 1 lM S100B did
not affect hEAG1 currents evoked at +40 mV (not shown).
The Ca2+ dependence of S100B was assayed at ﬁxed S100B
(500 nM) concentration and varying Ca2+ concentrations applied
to inside-out oocyte patches containing hEAG1 channels. The re-
sults from 3 to 9 patches are shown in Fig. 1E, superimposed with
a Hill ﬁt corresponding to an apparent IC50 value of 0.48 ± 0.36 lM
Ca2+ and a Hill coefﬁcient of 1.3 ± 0.33. The relative steady-state
current at inﬁnite Ca2+ concentration was estimated to 0.20 ±
0.20. Owing to the strong expression of Ca2+-activated chloride
channels in Xenopus oocytes, it was technically not feasible to test
Ca2+ concentrations higher than 4 lM. Given the half-maximal Ca2+
concentration of about 1 lM, the IC50 of Ca2+-saturated S100B to
block hEAG1 channels is expected to be below 100 nM.
3.2. S100B shares binding sites at hEAG1 channels with CaM
The similarity of functional effects of S100B and CaM on hEAG1
channels suggests a common mode of operation. It is not uncom-
mon for S100 proteins to bind to similar structural motifs as CaM
[23,24]. The cytosolic Ca2+/CaM-binding motifs in hEAG1 [8,9]
share similarity with a consensus binding motif described for
S100B [25] with the highest overlap in the C-terminal CaM-bindingsite C1, where a stretch of seven amino acids matches the con-
sensus +OXOXOO (+ = positive, O = hydrophobic, X = variable,
 = hydrophilic). Binding of S100B was therefore measured in
pull-down assays using GST fusions to CaM-binding protein frag-
ments. The construct GST-C2B34 (residues 649–867) comprising
the formerly identiﬁed CaM-binding sites C1 and C2 [9] exhibited
strong binding to S100B in the presence of Ca2+ (Fig. 2B). No bind-
ing was observed in C-terminal channel fragments with mutated
CaM-binding sites (GST-C2B34-C1: R675N-R677N-R681N-K682N
and GST-C2B34-C2: F714S-F717S) as well as in an N-terminal con-
struct (GST-N, 1-206) (Fig. 2A and B). This result shows that S100B
shares the C-terminal binding sites with CaM.
The expected competition of CaMandS100B for binding to the C1
and C2 sites (GST-C2B34) wasmeasured with FCS. For that purpose,
in aﬁrst stepbindingofﬂuorescently labeledCaMtoGST-C2B34was
detected as an increase in diffusion coefﬁcient. The ability of Ca2+-
saturated (25 lM) unlabeled S100B or unlabeled CaM to replace
the labeled CaM from its binding site was taken as a measure for
functional competition. The progressive replacement of labeled
CaM from the binding complex with increasing concentrations of
unlabeled S100B or CaM is shown in Fig. 2C. Data were ﬁtted with
Hill equations yielding half-maximal effective concentrations of
133 ± 19 nM for S100B and 29 ± 4 nM for unlabeled CaM, thus
clearly showing that S100BcompeteswithCaMforbinding tohEAG1
channel proteins.
Fig. 2. Binding of S100B to hEAG1 protein fragments. (A) Cartoon of an hEAG1 a subunit indicating the cytosolic protein parts used for interaction assays. Previously reported
binding sites for CaM are highlighted. (B) GST-pull-down assays were performed with the indicated GST-fusion proteins, or with GST alone. The proteins bound to GSH-
sepharose were incubated with S100B in the absence or presence of 25 lM free Ca2+ ions. After washing, the bound proteins were separated by SDS–PAGE and stained with
Coomassie blue. A second gel with identical loading pattern was used for Western blotting with a-S100B antibodies to detect the retained S100B protein (lower panel). (C)
S100B and CaM compete for binding to the C-terminal hEAG1 fragment GST-C2B34. Binding of Cy5-labeled MCGS-(H)6-hCaM (Cy5-CaM) to GST-C2B34 was monitored by
ﬂuorescence correlation spectroscopy. The diffusion time of Cy5-CaM was used to calculate the ratio of Cy5-CaM in complex with GST-2B34 in the presence of increasing
concentrations of S100B (circles) or unlabeled CaM (squares), respectively. Continuous curves are Hill ﬁts with half-maximal effective concentrations (EC50) of 133 ± 19 nM
for S100B and 29 ± 4 nM for unlabeled CaM. Hill coefﬁcients were 1.13 ± 0.17 and 1.68 ± 0.20, respectively.
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CaM-binding sites eliminates S100B binding. To test if this lack
of binding corresponds to an altered impact on channel function,
we compared hEAG1 wild type and channel mutants with
impaired C1 and C2 sites, as well as a construct with a deleted
N-terminus (hEAG1 DN) in inside-out patches. As shown in
Fig. 3A, application of 1 lM S100B in 1 lM Ca2+ potently inhibited
the hEAG1-mediated current, and upon wash with EGTA solution it
recovered from inhibition. Mutations in CaM-binding sites C1
(Fig. 3B) and C2 (Fig. 3C) abolished the sensitivity to both S100B
and CaM (n = 4). Deletion of the N-terminus also strongly reduced
the effect of S100B and CaM on hEAG1 channels (Fig. 3D, n = 4).
4. Discussion
Using a combination of biophysical and biochemical ap-
proaches we demonstrated that S100B is a potential regulator of
hEAG1 potassium channels. In a Ca2+-complexed form it inhibits
the channel in a 100-nanomolar concentration range and, hence,
can function as an alternative Ca2+ sensor for the potassium
channel. In comparison, CaM is more potent than S100B, half-
maximally inhibiting hEAG1 channels at about 6 nM. In both cases
channel inhibition is Ca2+ dependent. Our previous study demon-
strated that EAG channel availability is regulated just above basal
Ca2+ levels of resting cells with a half-maximal channel inhibition
at 100 nM Ca2+ [8,9]. S100B apparently needs about 500 nM Ca2+
for inhibiting hEAG1 channels. FCS interaction studies showed that
CaM and S100B compete for binding to a C-terminal duplet of
CaM-binding sites. Mutagenesis of these sites abolished physical
binding as well as the S100B impact on hEAG1 channels. Some-
what surprisingly, deletion of the N-terminus from the channel
strongly reduced the effect of S100B on hEAG1 current although
no direct binding of S100B to an N-terminal GST-fusion protein
could be detected. We therefore consider the N-terminus of hEAG1
channel as a low-afﬁnity S100B binding site and the C-terminus as
high afﬁnity binding site. It is also tempting to speculate that the
N-terminal binding site is part of a three-dimensional pocket thatincludes the C-terminal sites C1 and C2. This would imply that N-
terminal and C-terminal domains are in close proximity in the
functional channel. A somewhat similar scenario has been pro-
posed for the related hERG1 channel, where the N-terminal EAG
domain was found to interact closely with the core domain of
the channel [26].
Thus, hEAG1 potassium channels are an example of proteins
capable of binding both S100B and CaM, as documented for other
Ca2+-regulated proteins [24]. hEAG1 channels do not form stable
complexes with CaM in the absence of Ca2+. Consequently, upon
rising Ca2+ concentrations the channel has to compete for CaM
with a large variety of other CaM-regulated proteins as they are
found in every cell. Despite its lower binding afﬁnity, S100B could
be a relevant backup system when the local free CaM concentra-
tion is insufﬁcient to close all hEAG1 channels.
The S100B protein has been reported to be involved in numer-
ous physiological functions such as cell cycle progression, cell dif-
ferentiation, and cytoskeleton mediated interactions (for review
see [18,27]). Expression of S100B and hEAG1 is reported for hu-
man myoblast cells at the onset of fusion. hEAG1 channels were
found to promote myoblast differentiation [28,29], while intracel-
lular S100B interferes with this process [30]. The latter effect was
attributed to NF-kB-mediated downregulation of the transcription
factor MyoD, but inhibition of hEAG1 channels might as well con-
tribute to S100B effects on myoblast fusion. Furthermore, S100B is
prominently expressed in astrocytes and plays an important role
in modulation and differentiation of neuronal and glial cells
[31]. hEAG1 potassium channels are primarily found in neuronal
tissues, but no expression in astrocytes has been reported. How-
ever, potassium currents with EAG characteristics have been
recorded from astrocytoma cells (Tajima et al., unpublished).
EAG1 channels are upregulated in various cancer entities includ-
ing melanoma cancer cells [3]. High expression levels of S100B
are indicative of grade IV melanoma and have been associated
with the presence of metastases [32]. One therefore may specu-
late that in such tumor cells hEAG1 and S100B form functional
complexes.
Fig. 3. Impact of CaM-binding site mutations on current block by S100B and CaM.
Current recordings from inside-out patches under control conditions, in 1 lM
S100B with 1 lM Ca2+, wash with Ca2+-free solution, and 1 lM CaM with 1 lM Ca2+
for (A) wild type, (B) mutant C1, (C), mutant C2, and (D) DN. Depolarizations were
to +40 mV from a holding potential of 80 mV (wild type, C1 and C2) or 140 mV
(DN). All data in a row are from identical patches in a sequential order. In (D) CaM
concentration was 200 nM and no P/n correction was applied because of channel
activation below 100 mV.
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